Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
51
MRUS Quote, Financials, Valuation and Earnings
Last price:
$55.66
Seasonality move
:
12.54%
Day range:
$54.39 - $56.60
52-week range:
$33.19 - $62.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
66.65x
P/B ratio:
6.33x
Volume:
316K
Avg. volume:
1M
1-year change:
-2.86%
Market cap:
$3.8B
Revenue:
$36.1M
EPS (TTM):
-$4.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$9.9M | -$1.15 | 41.37% | -39.39% | $90.20 |
|
ARGX
argenx SE
|
$893.5M | $3.09 | 85.28% | 502.3% | $764.41 |
|
PHAR
Pharming Group
|
$82.5M | -$0.01 | 11.82% | -25% | $30.33 |
|
PHVS
Pharvaris NV
|
-- | -$0.90 | -- | -46.46% | $33.86 |
|
PRQR
ProQR Therapeutics NV
|
$5M | -$0.17 | -26.75% | -63.67% | $8.88 |
|
QURE
uniQure NV
|
$5.9M | -$0.90 | -49.23% | -25.47% | $36.24 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$54.50 | $90.20 | $3.8B | -- | $0.00 | 0% | 66.65x |
|
ARGX
argenx SE
|
$561.28 | $764.41 | $34.3B | 34.37x | $0.00 | 0% | 14.01x |
|
PHAR
Pharming Group
|
$10.00 | $30.33 | $683.9M | -- | $0.00 | 0% | 2.52x |
|
PHVS
Pharvaris NV
|
$25.12 | $33.86 | $1.4B | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$2.32 | $8.88 | $244.4M | -- | $0.00 | 0% | 10.48x |
|
QURE
uniQure NV
|
$14.40 | $36.24 | $788.4M | -- | $0.00 | 0% | 35.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRUS
Merus NV
|
-- | 0.551 | -- | 5.34x |
|
ARGX
argenx SE
|
-- | -0.134 | -- | 6.40x |
|
PHAR
Pharming Group
|
29.23% | -0.909 | 15.42% | 2.00x |
|
PHVS
Pharvaris NV
|
-- | -0.824 | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
5.57% | 1.651 | 3.6% | 4.01x |
|
QURE
uniQure NV
|
60.5% | -5.009 | 8.9% | 11.33x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
-- | -$75.7M | -45.56% | -45.56% | -285.94% | -$96.6M |
|
ARGX
argenx SE
|
$709.9M | $141.2M | 18.03% | 21.33% | 25.74% | -$147M |
|
PHAR
Pharming Group
|
$70.8M | -$7.4M | -4.46% | -6.48% | -8.46% | -$56K |
|
PHVS
Pharvaris NV
|
-- | -$44.4M | -- | -- | -- | -$40.7M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$11.4M | -53.43% | -58.1% | -239.35% | -$16.9M |
|
QURE
uniQure NV
|
$1.4M | -$39.3M | -158.75% | -333.08% | -1788.9% | -$44.2M |
Merus NV vs. Competitors
-
Which has Higher Returns MRUS or ARGX?
argenx SE has a net margin of -364.22% compared to Merus NV's net margin of 21.43%. Merus NV's return on equity of -45.56% beat argenx SE's return on equity of 21.33%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.40 $596.1M ARGXargenx SE89.78% $2.58 $5.5B -
What do Analysts Say About MRUS or ARGX?
Merus NV has a consensus price target of $90.20, signalling upside risk potential of 65.51%. On the other hand argenx SE has an analysts' consensus of $764.41 which suggests that it could grow by 36.19%. Given that Merus NV has higher upside potential than argenx SE, analysts believe Merus NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 ARGXargenx SE16 1 0 -
Is MRUS or ARGX More Risky?
Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison argenx SE has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.097%.
-
Which is a Better Dividend Stock MRUS or ARGX?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or ARGX?
Merus NV quarterly revenues are $26.5M, which are smaller than argenx SE quarterly revenues of $790.7M. Merus NV's net income of -$96.5M is lower than argenx SE's net income of $169.5M. Notably, Merus NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 34.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 66.65x versus 14.01x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV66.65x -- $26.5M -$96.5M ARGXargenx SE14.01x 34.37x $790.7M $169.5M
-
Which has Higher Returns MRUS or PHAR?
Pharming Group has a net margin of -364.22% compared to Merus NV's net margin of -18.61%. Merus NV's return on equity of -45.56% beat Pharming Group's return on equity of -6.48%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.40 $596.1M PHARPharming Group89.48% -$0.22 $303.7M -
What do Analysts Say About MRUS or PHAR?
Merus NV has a consensus price target of $90.20, signalling upside risk potential of 65.51%. On the other hand Pharming Group has an analysts' consensus of $30.33 which suggests that it could grow by 203.33%. Given that Pharming Group has higher upside potential than Merus NV, analysts believe Pharming Group is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 PHARPharming Group2 0 0 -
Is MRUS or PHAR More Risky?
Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRUS or PHAR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PHAR?
Merus NV quarterly revenues are $26.5M, which are smaller than Pharming Group quarterly revenues of $79.1M. Merus NV's net income of -$96.5M is lower than Pharming Group's net income of -$14.7M. Notably, Merus NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 66.65x versus 2.52x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV66.65x -- $26.5M -$96.5M PHARPharming Group2.52x -- $79.1M -$14.7M
-
Which has Higher Returns MRUS or PHVS?
Pharvaris NV has a net margin of -364.22% compared to Merus NV's net margin of --. Merus NV's return on equity of -45.56% beat Pharvaris NV's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.40 $596.1M PHVSPharvaris NV-- -$0.89 -- -
What do Analysts Say About MRUS or PHVS?
Merus NV has a consensus price target of $90.20, signalling upside risk potential of 65.51%. On the other hand Pharvaris NV has an analysts' consensus of $33.86 which suggests that it could grow by 34.8%. Given that Merus NV has higher upside potential than Pharvaris NV, analysts believe Merus NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 PHVSPharvaris NV7 0 0 -
Is MRUS or PHVS More Risky?
Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRUS or PHVS?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PHVS?
Merus NV quarterly revenues are $26.5M, which are larger than Pharvaris NV quarterly revenues of --. Merus NV's net income of -$96.5M is lower than Pharvaris NV's net income of -$48.8M. Notably, Merus NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 66.65x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV66.65x -- $26.5M -$96.5M PHVSPharvaris NV-- -- -- -$48.8M
-
Which has Higher Returns MRUS or PRQR?
ProQR Therapeutics NV has a net margin of -364.22% compared to Merus NV's net margin of -223.04%. Merus NV's return on equity of -45.56% beat ProQR Therapeutics NV's return on equity of -58.1%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.40 $596.1M PRQRProQR Therapeutics NV-- -$0.11 $90.5M -
What do Analysts Say About MRUS or PRQR?
Merus NV has a consensus price target of $90.20, signalling upside risk potential of 65.51%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 282.54%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 PRQRProQR Therapeutics NV6 0 0 -
Is MRUS or PRQR More Risky?
Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.365, suggesting its less volatile than the S&P 500 by 63.535%.
-
Which is a Better Dividend Stock MRUS or PRQR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PRQR?
Merus NV quarterly revenues are $26.5M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.8M. Merus NV's net income of -$96.5M is lower than ProQR Therapeutics NV's net income of -$10.6M. Notably, Merus NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 66.65x versus 10.48x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV66.65x -- $26.5M -$96.5M PRQRProQR Therapeutics NV10.48x -- $4.8M -$10.6M
-
Which has Higher Returns MRUS or QURE?
uniQure NV has a net margin of -364.22% compared to Merus NV's net margin of -2784.75%. Merus NV's return on equity of -45.56% beat uniQure NV's return on equity of -333.08%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.40 $596.1M QUREuniQure NV87.43% -$0.82 $85.3M -
What do Analysts Say About MRUS or QURE?
Merus NV has a consensus price target of $90.20, signalling upside risk potential of 65.51%. On the other hand uniQure NV has an analysts' consensus of $36.24 which suggests that it could grow by 151.68%. Given that uniQure NV has higher upside potential than Merus NV, analysts believe uniQure NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 QUREuniQure NV9 2 0 -
Is MRUS or QURE More Risky?
Merus NV has a beta of 0.997, which suggesting that the stock is 0.282% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.077, suggesting its less volatile than the S&P 500 by 92.298%.
-
Which is a Better Dividend Stock MRUS or QURE?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or QURE?
Merus NV quarterly revenues are $26.5M, which are larger than uniQure NV quarterly revenues of $1.6M. Merus NV's net income of -$96.5M is lower than uniQure NV's net income of -$43.6M. Notably, Merus NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 66.65x versus 35.52x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV66.65x -- $26.5M -$96.5M QUREuniQure NV35.52x -- $1.6M -$43.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
INKT alert for Jul 15
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Sell
48
NEGG alert for Jul 15
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
77
VBTX alert for Jul 15
Veritex Holdings [VBTX] is up 19.56% over the past day.
